A Phase I study to evaluate the saftey, phamocokinetics and pharmacodynamics of JNJ-42756493 a pan-fibroblat growth factor receptor.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
August 1, 2014
End Date
June 18, 2018
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
August 1, 2014
End Date
June 18, 2018